Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 417-426

  Zamboni, William C ^a,b,c   Strychor, Sandra ^c   Joseph, Erin ^c   Parise, Robert A ^c   Egorin, Merrill J ^b,c   Eiseman, Julie L ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

9 Nitrocamptothecin; Docetaxel; Ovarian xenografts; Tumor retention

Indexed keywords

DOCETAXEL; PACLITAXEL; RUBITECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RETENTION; DRUG SENSITIVITY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; FEMALE; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TAXOIDS; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45749140096     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0620-7     Document Type: Article

References (63)

1. Ozols RF, Schwartz PE, Eifel PJ (1997) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practices of oncology. Lippincott-Raven, Philadelphia, pp 1502-1534
2. Shah MA, Schwartz GK (2000) The relevance of drug sequence in combination chemotherapy. Drug Resist Updat 3:335-356
3. Kwong MS, Bleickardt E, Murren JR (2002) Camptothecin and taxane regimens for small-cell lung cancer. Oncology (Williston Park) 16:33-38
4. Hobday TJ (2005) An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 5(Suppl 1):S11-S18
5. Socinski MA, Baggstrom MQ, Hensing TA (2003) Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol 1:33-38
6. Ahn JH, Kim SB, Sohn HJ, Lee JS, Kang YK, Kun KW (2005) Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast 14:304-309
7. Takahashi N, Li W, Banerjee D et al (2002) Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62:6909-6915
8. Posey JA, Wang H, Hamilton J et al (2005) Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol 56:182-188
9. Zamboni WC, Egorin MJ, Van Echo DA et al (2000) Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 18:3288-3294
10. Rowinsky EK (2005) Antimicrotubule agents. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott/Williams & Wilkins, Philadelphia/Baltimore, pp 237-283
11. Sparreboom A, Zamboni WC (2005) Topoisomerase I targeted drugs. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott/Williams & Wilkins, Philadelphia/Baltimore, pp 371-414
12. Polyzos A, Kosmas C, Toufexi H et al (2005) Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25:3559-3564
13. Garcia AA, Pujari M, Jeffers S et al (2005) Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol 56:75-82
14. O'Reilly S (1999) Topotecan: what dose, what schedule, what route? Clin Cancer Res 5:3-5
15. Hong WK (2002) The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review. Oncology (Williston Park) 16:9-15
16. Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5-30
17. Engels FK, Verweij J (2005) Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41:1117-1126
18. Gervais R, Ducolone A, Breton JL et al (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16:90-96
19. Stemmler J, Mair W, Stauch M et al (2005) High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 68:71-78
20. Ramanathan RK, Ramalingam S, Egorin MJ et al (2005) Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 55:354-360
21. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
22. Zamboni WC, Jung LL, Egorin MJ et al (2004) Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res 10:5058-5064
23. Schoffski P, Herr A, Vermorken JB et al (2002) Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 38:807-813
24. Ebrahimi B, Phan A, Yao J et al (2002) Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc Am Soc Clin Oncol 21:596a
25. Konstadoulakis MM, Antonakis PT, Tsibloulis BG et al (2001) A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48:417-420
26. Natelson EA, Giovanella BC, Verschraegen CF et al (1996) Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9- nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 803:224-230
27. Furman WL, Stewart CF, Poquette CA et al (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824
28. Thompson J, Stewart CF, Houghton PJ (1998) Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1400:301-319
29. Houghton PJ, Cheshire PJ, Hallman JD et al (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403
30. Zamboni WC, Stewart CF, Thompson J et al (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505-511
31. Jung LL, Ramanathan RK, Egorin MJ et al (2004) Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother Pharmacol 54:487-496
32. Zamboni WC, Bowman LC, Tan M et al (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454-460
33. Drengler RL, Kuhn JG, Schaaf LJ et al (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696
34. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689
35. Gounder M, Saleem A, Roychowdhury M (2001) Metabolism of 9-nitrocamptothecan (RFS2000/9NC) to 9-aminocamptothecan (9AC) in patients and in vitro. Proc Am Assoc Cancer Res 42:537
36. Miller KD, Soule SE, Haney LG et al (2004) A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Invest New Drugs 22:69-73
37. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469
38. Zamboni WC, Jung LL, Egorin MJ et al (2005) Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clin Cancer Res 11:4867-4874
39. Scripture CD, Sparreboom A, Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780-789
40. Engels FK, Sparreboom A, Mathot RA, Verweij J (2005) Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 93:173-177
41. Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R (2005) Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 11:6972-6979
42. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A (1998) Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 34:33-46
43. Kirstein MN, Houghton PJ, Cheshire PJ et al (2001) Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 7:358-366
44. Eiseman JL, Lan J, Lagattuta TF et al (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55:21-32
45. Britten CD, Hilsenbeck SG, Eckhardt SG et al (1999) Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59:1049-1053
46. Villena-Heinsen C, Friedrich M, Ertan AK, Farnhammer C, Schmidt W (1998) Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride. Anticancer Drugs 9:557-563
47. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6:339-8
48. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783:231-236
49. Zamboni WC, Goel S, Iqbal T et al (2006) Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chemother Pharmacol 57:631-639
50. D'Argenio DZ, Schmuitzky A (1990) ADAPT II User's Guide: Biomedical Simulations Resource
51. Rowland M, Tozer T (1999) Clinical pharmacokinetics: concepts and applications. Lea and Febiger, Philadelphia
52. Grever MR, Chabner BA, Shoemaker D (1997) Cancer drug discovery and development. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practices of oncology. Lippincott-Raven, Philadelphia, pp 385-393
53. Grever MR (1996) Cancer drug screening. In: Schilsky RL (eds) Principles of antineoplastic drug development and pharmacology. Marcel Dekker Inc., New York
54. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1994) A comparison of two phase I trial designs. Stat Med 13:1799-1806
55. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17
56. Eiseman JL, Eddington ND, Leslie J et al (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465-471
57. Eiseman JL, Eddington ND, Leslie J et al (1993) Pharmacokinetics and development of a physiologic model of Taxol in CD2F1 mice. Proc Am Assoc Cancer Res 34:396
58. Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH (2002) Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 49:499-503
59. Zamboni WC (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11:8230-8234
60. Papahadjopoulos D, Allen TM, Gabizon A et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumore therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464
61. Ibrahim NK, Desai N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044
62. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185-219
63. Madden T, Newman RA, Antoun G, Johansen MJ, Ali-Osman F (1998) Low-level taxane exposure increases the activity of topoisomerase I targeted agents. Proc Am Soc Clin Oncol 17:3554